You have full access to this article via your institution. The authors suggest that screening for NPM1 mutations will be useful for risk assessment in patients with newly diagnosed AML.

Secondary-type Mutations in NPM1-mutated AML-MRC With a History of MDS or MDS/MPN Do secondary mutations explain why patients with AML with a history of myelodysplasia-related changes and the NPM1 ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Ziftomenib, Kura's most advanced drug candidate, targets AML with NPM1 mutations, showing promising Phase 1b and a ...

mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor. The primary endpoint was met ...

Other analyses of Black patients found that mutations in NPM1 and NRAS genes were associated with inferior disease-free ...

The mutation types being explored are AML patients with KMT2Ar and mNPM1 types. It is said that about 30% of AML patients have the NPM1 mutant subtype and then about 10% of AML and Acute ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...

The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and ...